HPV causes cancer. Help protect your kids.
Survival statistics for eye cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular person’s chances of survival.
There are many different ways to measure and report cancer survival statistics. Your doctor can explain the statistics for eye cancer and what they mean to you.
Relative survival looks at how likely people with cancer are to survive after their diagnosis compared to people in the general population who do not have cancer, but who share similar characteristics (such as age and sex).
In Canada, a 5-year relative survival statistic is reported for eye cancer. The 5-year relative survival for eye cancer is 77%. This means that, on average, people diagnosed with eye cancer are 77% as likely to live 5 years after their diagnosis as people in the general population.
Survival varies with each type, stage (size of the tumour) and location of the eye cancer. The following factors can also affect survival for eye cancer.
There are no specific Canadian statistics available for the different stages or types of eye cancer. The following information comes from a variety of sources and may include statistics from other countries.
|Location of tumour||5-year relative survival|
Difficult to determine because this tumour is rare, but generally has a poor prognosis.
For people with metastatic disease, the median survival is generally 2–9 months. Median survival is the period of time (usually months or years) at which half of the people with cancer are still alive. The other half will live less than this amount of time.
People with cancer should talk to their doctor about their prognosis. Prognosis depends on many factors, including:
Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.
A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.